Dasatinib-induced reversible pulmonary arterial hypertension in a pediatric patient with BCR/ABL1+ lymphoblastic lymphoma from chronic myeloid leukemia.
[Pulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report].
Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.
Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?
Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient.